shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299 ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering along with ...

The company announced that it has entered into an option and license agreement with MSD (which is the tradename of Merck & Co., Inc., Rahway, NJ) (NYSE:MRK) for two preclinical vaccine candidates.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with ...

BI-1910 is being evaluated both as single agent (Part A) and in combination (Part B) with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab). Single agent dose ...